Annals of Oncology March 2024 issue article of the month

Annals of Oncology shared a post by Annals of Oncology on X/Twitter, adding:

”The article by Giorgio Bogani and collaborators on immunotherapy in advanced endometrial cancer is the Annals of Oncology March 2024 issue article of the month.

A tutorial:

Results of a meta-analysis of the 4 RCTs evaluating immunotherapy and chemotherapy in first line endometrial cancer. Platinum-based chemotherapy was the standard of care since the results of the GOG209 trial. Immunotherapy transformed the current landscape.

In 2023, the preliminary results of studies testing anti-PD-1/PD-L1 in combination with 1st line chemotherapy were released. In all comers, chemotherapy plus immunotherapy followed by immunotherapy prolong response rate in advanced /metastatic endometrial cancers.

PD(L)1 drugs improve outcomes regardless of MMR status . Immunotherapy and chemotherapy combinations showed activity in endometrial cancer, particularly in MMRd disease.

Even in the MMR preserved population, immunotherapy correlates with improved outcomes (to a lesser extent). Adding immunotherapy provides a clinically meaningful trend in reduced risk of death by about 20%.

Addition of PARPi (olaparib) to anti-PDL-1 (durvalumab) enhanced PFS benefit in the MMRp/MSS and the PD-L1–positive subgroups, regardless of HRR status.

Non-responsive patients necessitate more precise and effective treatment modalities Ongoing trials are testing trastuzumab deruxtecan (T-DXd), selinexor, WEE1 inhibitors and CDK4/6 inhibitors.

Giorgio Bogani sets the stage and explains what to expect in this video from the video highlights series.”

Quoting Annals of Oncology’s post:

”Just out in Annals of Oncology, a review and meta-analysis by Giorgio Bogani and collaborators of phase III trials investigating the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer. Read further.

They assess:

• The role of frontline immuno-oncology.
• The role of combination of chemo and immunotherapy in MMRd endometrial cancer.
• The role of combination of chemo and immunotherapy in MMRp endometrial cancers.
• Molecular-based therapy.
• Biomarker-driven therapy.”

Source: Annals of Oncology/X and Annals of Oncology/X